News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
286,645 Results
Type
Article (15191)
Company Profile (298)
Press Release (271148)
Multimedia
Podcasts (95)
Webinars (12)
Section
Business (79971)
Career Advice (163)
Deals (13398)
Drug Delivery (43)
Drug Development (50807)
Employer Resources (32)
FDA (5894)
Job Trends (5188)
News (145396)
Policy (10091)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Standard (3)
Academia (937)
Accelerated approval (25)
Adcomms (14)
Allergies (100)
Alliances (21770)
ALS (157)
Alzheimer's disease (1112)
Antibody-drug conjugate (ADC) (354)
Approvals (6153)
Artificial intelligence (336)
Autoimmune disease (218)
Automation (10)
Bankruptcy (105)
Best Places to Work (4563)
BIOSECURE Act (6)
Biosimilars (117)
Biotechnology (230)
Bladder cancer (118)
Brain cancer (57)
Breast cancer (407)
Cancer (3789)
Cardiovascular disease (278)
Career advice (151)
Career pathing (8)
CAR-T (255)
CDC (7)
Celiac Disease (1)
Cell therapy (673)
Cervical cancer (21)
Clinical research (44572)
Collaboration (1395)
Company closure (3)
Compensation (719)
Complete response letters (54)
COVID-19 (1118)
CRISPR (104)
C-suite (719)
Cystic fibrosis (117)
Data (5340)
Denatured (20)
Depression (110)
Dermatology (50)
Diabetes (296)
Diagnostics (1434)
Digital health (16)
Diversity (5)
Diversity, equity & inclusion (10)
Drug discovery (247)
Drug pricing (52)
Drug shortages (3)
Duchenne muscular dystrophy (266)
Earnings (32531)
Editorial (33)
Employer branding (4)
Employer resources (30)
Events (52910)
Executive appointments (677)
FDA (7986)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (14)
Frontotemporal dementia (30)
Funding (1150)
Gene editing (219)
Generative AI (29)
Gene therapy (581)
GLP-1 (550)
Government (1179)
Grass and pollen (3)
Guidances (172)
Healthcare (6662)
HIV (26)
Huntington's disease (50)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (83)
Immunology and inflammation (228)
Immuno-oncology (69)
Indications (121)
Infectious disease (1263)
Inflammatory bowel disease (181)
Inflation Reduction Act (10)
Influenza (54)
Intellectual property (195)
Interviews (18)
IPO (7365)
IRA (13)
Job creations (869)
Job search strategy (130)
JPM (41)
Kidney cancer (9)
Labor market (27)
Layoffs (250)
Leadership (12)
Legal (1405)
Liver cancer (44)
Longevity (23)
Lung cancer (497)
Lymphoma (283)
Machine learning (33)
Management (7)
Manufacturing (481)
MASH (150)
Medical device (2697)
Medtech (2712)
Mergers & acquisitions (6744)
Metabolic disorders (853)
mRNA (147)
Multiple sclerosis (119)
NASH (14)
Neurodegenerative disease (299)
Neuropsychiatric disorders (81)
Neuroscience (2216)
Neurotech (1)
NextGen: Class of 2026 (2038)
Non-profit (876)
Now hiring (38)
Obesity (386)
Opinion (138)
Ovarian cancer (168)
Pain (129)
Pancreatic cancer (206)
Parkinson's disease (280)
Partnered (12)
Patents (371)
Patient recruitment (469)
Peanut (47)
People (27084)
Pharmaceutical (42)
Pharmacy benefit managers (6)
Phase 1 (15790)
Phase 2 (20747)
Phase 3 (13073)
Pipeline (5265)
Policy (102)
Postmarket research (853)
Preclinical (6707)
Press Release (30)
Prostate cancer (183)
Psychedelics (58)
Radiopharmaceuticals (270)
Rare diseases (825)
Real estate (1457)
Recruiting (12)
Regulatory (10421)
Reports (20)
Research institute (981)
Resumes & cover letters (20)
Rett syndrome (32)
RNA editing (25)
RSV (24)
Schizophrenia (144)
Series A (225)
Series B (155)
Service/supplier (1)
Sickle cell disease (89)
Special edition (19)
Spinal muscular atrophy (124)
Sponsored (17)
Startups (2026)
State (1)
Stomach cancer (5)
Supply chain (38)
Tariffs (19)
The Weekly (73)
Vaccines (383)
Venture capital (83)
Weight loss (206)
Women's health (42)
Worklife (2)
Date
Today (121)
Last 7 days (531)
Last 30 days (1897)
Last 365 days (17975)
2026 (6646)
2025 (18098)
2024 (20540)
2023 (22421)
2022 (26829)
2021 (27808)
2020 (23359)
2019 (16231)
2018 (11745)
2017 (13751)
2016 (11847)
2015 (14356)
2014 (10399)
2013 (7484)
2012 (7535)
2011 (7614)
2010 (7433)
Location
Africa (154)
Alabama (71)
Alaska (2)
Arizona (82)
Arkansas (6)
Asia (18564)
Australia (3182)
California (8182)
Canada (2110)
China (941)
Colorado (294)
Connecticut (307)
Delaware (279)
Europe (39905)
Florida (1046)
Georgia (240)
Hawaii (2)
Idaho (17)
Illinois (477)
India (43)
Indiana (191)
Iowa (8)
Japan (281)
Kansas (82)
Kentucky (11)
Louisiana (12)
Maine (12)
Maryland (850)
Massachusetts (6482)
Michigan (123)
Minnesota (289)
Mississippi (3)
Missouri (35)
Montana (17)
Nebraska (6)
Nevada (44)
New Hampshire (22)
New Jersey (1874)
New Mexico (13)
New York (2031)
North Carolina (954)
North Dakota (6)
Northern California (4118)
Ohio (205)
Oklahoma (11)
Oregon (23)
Pennsylvania (1507)
Puerto Rico (11)
Rhode Island (27)
South America (216)
South Carolina (12)
Southern California (3274)
Tennessee (49)
Texas (1097)
United States (27026)
Utah (112)
Virginia (170)
Washington D.C. (37)
Washington State (672)
West Virginia (1)
Wisconsin (53)
286,645 Results for "juno therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
JUNO OTC, A WHOLLY-OWNED SUBSIDIARY OF LSL PHARMA GROUP, SIGNS BINDING TERM SHEET WITH INSTAPILL PRIVATE LIMITED TO SUPPLY PRIVATE LABEL LORATADINE 10 MG RDT IN CANADA
April 9, 2026
·
4 min read
Press Releases
LSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND FINAL $2M CLOSING OF UPSIZED $12M OFFERING
December 24, 2025
·
6 min read
Biotech Beach
JUNO DIAGNOSTICS™ EXPANDS ITS PRODUCT PORTFOLIO WITH THE LAUNCH OF JUNO HAZEL™ PLUS AND ANNOUNCES EARLY ACCESS PROGRAM (EAP) FOR INNOVATIVE NIPS TESTS
Juno Diagnostics™ (JunoDx™) today announced the expansion of its product portfolio with the launch of Juno Hazel™ Plus, a non-invasive prenatal screening (NIPS, also known as NIPT) solution enabled through finger-prick amounts of blood, and the creation of an Early Access Program (EAP)
January 9, 2023
·
4 min read
Deals
Juno Pharmaceuticals Acquires Omega Laboratories, Propelling Canada’s Pharmaceutical Industry Forward
Today, Juno Pharmaceuticals Canada announced the acquisition of Omega Laboratories (“Omega”), one of Canada’s largest domestic specialty injectable pharmaceutical manufacturers.
May 15, 2023
·
3 min read
Biotech Beach
JUNO DIAGNOSTICS™ ANNOUNCES LAUNCH OF JUNO HAZEL™, AN INNOVATIVE SOLUTION TO INCREASE ACCESSIBILITY AND AFFORDABILITY OF NON-INVASIVE PRENATAL SCREENING (NIPS)
Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced the launch of Juno Hazel™, a non-invasive prenatal screening (NIPS) solution enabled from finger-prick amounts of blood.
November 17, 2022
·
3 min read
Juno Pharmaceuticals receives approval to import Eptifibatide as Canadian hospitals continue to grapple with shortages of critical medicines
Juno Pharmaceuticals Canada (“Juno”), a Canadian specialty pharmaceutical company, announced that it has received approval from Health Canada to import Eptifibatide solution for infusion and injection (“Eptifibatide”) pursuant to Health Canada’s exceptional importation and sale guidelines.
March 29, 2023
·
2 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Press Releases
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
April 27, 2026
·
6 min read
Business
Juno Pharmaceuticals Partners With Rosemont Pharmaceuticals as Exclusive Canadian Distributor to Offer Previously Inaccessible Medicines
Juno Pharmaceuticals Canada announced its partnership with U.K. based developer, manufacturer and global supplier of novel, Rx, oral liquid medicines, Rosemont Pharmaceuticals (“Rosemont”), as its exclusive Canadian distributor.
April 25, 2023
·
3 min read
Juno Pharmaceuticals Approved to Import Ketamine, Providing Immediate Relief for Hospitals Across Canada
Juno Pharmaceuticals Canada, a Canadian specialty pharmaceutical company, announced it has received approval from Health Canada to import ketamine solution for injection pursuant to Health Canada’s exceptional importation and sale guidelines.
May 4, 2023
·
2 min read
1 of 28,665
Next
